Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 84
Filtrar
1.
Hum Immunol ; 83(5): 428-436, 2022 May.
Artigo em Inglês | MEDLINE | ID: mdl-35177260

RESUMO

BACKGROUND: Common Variable Immunodeficiency (CVID) is a heterogeneous disorder characterized by defective B cell differentiation and antibody production. Interleukin (IL)-21 activates STAT3, a potent regulator of B cell differentiation into plasma cells. We have studied the phosphorylation of STAT3 in CVID patients and its contribution to B cells subsets. METHODS: We studied 23 CVID patients and 14 healthy donors (HD), determining pSTAT3 in naïve and memory B cells, stimulated with IL-21 at 15 and 60 min. RESULTS: pSTAT3 was increased in total (p = 0.044), naïve (p = 0.023), and memory (p = 0.001) B cells at 60 min in CVID patients compared with HD. We classified patients by the percentage of isotype-switched memory B cells. We observed an increase in pSTAT3 at 60 min in memory B cells in both CVID groups of patients (p = 0.026, p = 0.007, respectively). Interestingly, the analysis of each group individually; demonstrated that patients with decreased memory B cells exhibited an increase in pSTAT3 at 60 min (p = 0.023), while HD had an expected decrease in pSTAT3 (p = 0.045). CONCLUSION: CVID patients showed an increased atypical of pSTAT3, which could affect the differentiation of B cells. Further studies in the IL-21 pathway are necessary to understand how this alteration could promote differentiation defects in patient B cells.


Assuntos
Subpopulações de Linfócitos B , Imunodeficiência de Variável Comum , Linfócitos B , Imunodeficiência de Variável Comum/metabolismo , Humanos , Ativação Linfocitária , Fosforilação , Fator de Transcrição STAT3/metabolismo
2.
Rev Med Inst Mex Seguro Soc ; 59(6): 545-550, 2021 11 01.
Artigo em Espanhol | MEDLINE | ID: mdl-34910416

RESUMO

Background: The SARS-CoV-2 disease, called COVID-19, emerged in China has acquired pandemic dimensions. According to the WHO situational report of March 15, 2021, the global fatality rate is 2.2%; in Mexico, around 194 944 deaths have been confirmed by COVID-19. Studies in China identified that patients with severe COVID-19, when compared with those who had non-severe COVID-19, presented more severe neurological manifestations. Objective: To determine the frequency of neurological symptoms and manifestations in patients with severe COVID-19 in a tertiary care center. Material and methods: A cross-sectional, observational and analytical study was carried out at the Hospital de Especialidades del Centro Médico Nacional Siglo XXI, in patients hospitalized with severe COVID-19. Results: 183 cases were analyzed, of which 130 were men (71%). The median age was 55 years (IQR: 44-65). The neurological symptoms were: headache, anosmia and dysgeusia. Neurological manifestations occurred in 27 patients (16%), the most frequent was ischemic-type cerebrovascular disease (CVD) in 12 (44%), in patients older than 76.5 years vs. 54 years (p = 0.000), with history of cardiovascular disease. Conclusions: The most frequent neurological symptoms were headache, anosmia and dysgeusia. The most frequent neurological manifestation was ischemic CVD that appeared in older patients with severe COVID-19 with a history of cardiovascular disease.


Introducción: la enfermedad por SARS-CoV-2 denominada COVID-19 originada en China adquirió dimensiones pandémicas. De acuerdo con el reporte situacional de la OMS al 15 de marzo de 2021, la tasa de letalidad global es del 2.2%; en México se han confirmado alrededor de 194 944 defunciones por COVID-19. Estudios en China identificaron que los pacientes con COVID-19 severo, al compararlos con aquellos que cursaron con COVID-19 no severo, presentaron manifestaciones neurológicas más graves. Objetivo: determinar la frecuencia de síntomas y manifestaciones neurológicas en pacientes con COVID-19 severo en un centro de tercer nivel de atención. Material y métodos: estudio transversal, observacional y analítico, llevado a cabo en el Hospital de Especialidades del Centro Médico Nacional Siglo XXI, en pacientes hospitalizados con COVID-19 severo. Resultados: se analizaron 183 casos, de los cuales 130 eran hombres (71%). La mediana de edad fue de 55 años (RIC: 44-65). Los síntomas neurológicos fueron: cefalea, anosmia y disgeusia. Las manifestaciones neurológicas se presentaron en 27 pacientes, la más frecuente fue la enfermedad vascular cerebral tipo isquémica (EVC) en 12 pacientes (44%) en pacientes con mayor edad, 76.5 frente a 54 años (p = 0.000), y con antecedente de enfermedad cardiovascular. Conclusiones: los síntomas neurológicos más frecuentes fueron cefalea, anosmia y disgeusia. La manifestación neurológica más frecuente fue la EVC isquémica que se presentó en pacientes con COVID-19 severo de mayor edad y con antecedente de enfermedad cardiovascular.


Assuntos
COVID-19 , Doenças do Sistema Nervoso , Idoso , Estudos Transversais , Humanos , Masculino , Pessoa de Meia-Idade , Doenças do Sistema Nervoso/diagnóstico , Doenças do Sistema Nervoso/epidemiologia , Doenças do Sistema Nervoso/etiologia , SARS-CoV-2 , Centros de Atenção Terciária
3.
Rev. Méd. Inst. Mex. Seguro Soc ; Rev. Méd. Inst. Mex. Seguro Soc;59(6): 545-550, dic. 2021. tab, graf
Artigo em Espanhol | LILACS | ID: biblio-1357564

RESUMO

Introducción: la enfermedad por SARS-CoV-2 denominada COVID-19 originada en China adquirió dimensiones pandémicas. De acuerdo con el reporte situacional de la OMS al 15 de marzo de 2021, la tasa de letalidad global es del 2.2%; en México se han confirmado alrededor de 194 944 defunciones por COVID-19. Estudios en China identificaron que los pacientes con COVID-19 severo, al compararlos con aquellos que cursaron con COVID-19 no severo, presentaron manifestaciones neurológicas más graves. Objetivo: determinar la frecuencia de síntomas y manifestaciones neurológicas en pacientes con COVID-19 severo en un centro de tercer nivel de atención. Material y métodos: estudio transversal, observacional y analítico, llevado a cabo en el Hospital de Especialidades del Centro Médico Nacional Siglo XXI, en pacientes hospitalizados con COVID-19 severo. Resultados: se analizaron 183 casos, de los cuales 130 eran hombres (71%). La mediana de edad fue de 55 años (RIC: 44-65). Los síntomas neurológicos fueron: cefalea, anosmia y disgeusia. Las manifestaciones neurológicas se presentaron en 27 pacientes, la más frecuente fue la enfermedad vascular cerebral tipo isquémica (EVC) en 12 pacientes (44%) en pacientes con mayor edad, 76.5 frente a 54 años (p = 0.000), y con antecedente de enfermedad cardiovascular. Conclusiones: los síntomas neurológicos más frecuentes fueron cefalea, anosmia y disgeusia. La manifestación neurológica más frecuente fue la EVC isquémica que se presentó en pacientes con COVID-19 severo de mayor edad y con antecedente de enfermedad cardiovascular.


Background: The SARS-CoV-2 disease, called COVID-19, emerged in China has acquired pandemic dimensions. According to the WHO situational report of March 15, 2021, the global fatality rate is 2.2%; in Mexico, around 194 944 deaths have been confirmed by COVID-19. Studies in China identified that patients with severe COVID-19, when compared with those who had non-severe COVID-19, presented more severe neurological manifestations. Objective: To determine the frequency of neurological symptoms and manifestations in patients with severe COVID-19 in a tertiary care center. Material and methods: A cross-sectional, observational and analytical study was carried out at the Hospital de Especialidades del Centro Médico Nacional Siglo XXI, in patients hospitalized with severe COVID-19. Results: 183 cases were analyzed, of which 130 were men (71%). The median age was 55 years (IQR: 44-65). The neurological symptoms were: headache, anosmia and dysgeusia. Neurological manifestations occurred in 27 patients (16%), the most frequent was ischemic-type cerebrovascular disease (CVD) in 12 (44%), in patients older than 76.5 years vs. 54 years (p = 0.000), with history of cardiovascular disease. Conclusions: The most frequent neurological symptoms were headache, anosmia and dysgeusia. The most frequent neurological manifestation was ischemic CVD that appeared in older patients with severe COVID-19 with a history of cardiovascular disease.


Assuntos
Humanos , Masculino , Feminino , Atenção Terciária à Saúde , Transtornos Cerebrovasculares , COVID-19 , Manifestações Neurológicas , Atenção Terciária à Saúde , Cefaleia
4.
J Clin Immunol ; 41(7): 1463-1478, 2021 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-34114122

RESUMO

INTRODUCTION: Patients with inborn errors of immunity (IEI) have a compromised or inappropriate immune response. Although they might be considered a high-risk group for severe SARS-CoV-2 infection, the reported impact of COVID-19 in these patients has been reassuring, while the differential susceptibility of distinct types of IEI remains unclear. OBJECTIVE: We aimed to describe the findings and outcomes of our known patients with IEI who were diagnosed with COVID-19. METHODS: In a retrospective study from March 2020 to February 2021, four centers in Mexico collected clinical, laboratory, and genetic data from pediatric and adult patients with known diagnoses of IEI who presented with COVID-19, based on compatible symptoms and positive SARS-CoV-2 testing or known household exposure. RESULTS: We report 31 patients with known IEI from Mexico who presented with SARS-CoV-2 infection. Seventy-four percent were male, 52% were pediatric, and 81% survived. Their ages ranged from 5 months to 56 years, with a median of 17 years. Sixty-five percent had predominant antibody deficiencies, 48% were hospitalized, and 26% required ICU. Pediatric patients had a higher hospital admission rate than adults. Inpatient mortality was 40%, and ICU mortality rate was 63%. Forty-eight percent developed pneumonia, while 36% had evidence of hyperinflammation (4 adults and 7 children). Predominant laboratory features were lymphopenia and thrombocytopenia, seen in 70 and 44% of patients, respectively. The serum D-dimer median value was 2.6 (0.5-20.6) µg/mL, and the median highest ferritin value was 1015 (32-10,303) ng/mL. Intravenous immunoglobulin was used in 80% of patients. Other treatments included macrolides (39%) and corticosteroids (29%). Six patients died from secondary infection or uncontrolled systemic inflammation. DISCUSSION: Although impaired immunity due to IEI may be a predisposing factor for severe COVID-19, most of our patients with IEI who acquired the SARS-CoV-2 infection developed a well-tolerated infection and survived, as have more than 80% of worldwide reported patients to date. An impaired immune or inflammatory response may be a predisposing factor for some and a protective factor for others. A systematic review of the literature could help identify those patients at risk of severe disease and complications. Healthcare-associated infections should be aggressively prevented.


Assuntos
COVID-19/diagnóstico , Doenças da Imunodeficiência Primária/diagnóstico , SARS-CoV-2/fisiologia , Adolescente , Adulto , COVID-19/epidemiologia , COVID-19/mortalidade , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Masculino , México/epidemiologia , Pessoa de Meia-Idade , Doenças da Imunodeficiência Primária/epidemiologia , Doenças da Imunodeficiência Primária/mortalidade , Estudos Retrospectivos , Risco , Índice de Gravidade de Doença , Análise de Sobrevida , Adulto Jovem
5.
Gac Med Mex ; 154(5): 588-597, 2018.
Artigo em Espanhol | MEDLINE | ID: mdl-30407467

RESUMO

Multiple sclerosis is a demyelinating inflammatory disease that affects the central nervous system. Its etiology is the result of a complex interaction between genetic and environmental factors that trigger a deregulated immune response, with the resulting inflammation and neuronal/axonal degeneration. Neuroinflammation is triggered when peripheral leukocytes migrate to the central nervous system and release cytokines such as interleukins 1 and 6 (IL-1 and 6) and tumor necrosis factor (TNF), which act on dwelling cells. The innate immune system plays an important role in the onset and progression of the disease by identifying molecular patterns associated with pathogens and damage, which modulate effector and regulatory functions of the cells where they are expressed, in order to direct the specific immune response. Th17 cells favor the disruption of the blood-brain barrier, which enables the migration of leukocytes to the central nervous system and the triggering of the inflammatory cascade; the Th1 profile (IL-1, IL-6) collaborates to perpetuate it. B-cell function is to produce antibodies and cytokines (IL-6, IL-12 and TFN). Knowledge on multiple sclerosis pathophysiology will enable the development of new therapeutic options that impact on natural history of the disease and its prognosis.


La esclerosis múltiple es una enfermedad inflamatoria desmielinizante que afecta el sistema nervioso central. Su etiología es el resultado de una compleja interacción entre factores genéticos y ambientales que desencadenan una respuesta inmune desregulada, con la consiguiente inflamación y degeneración neuronal/axonal. La neuroinflamación se desencadena cuando los leucocitos periféricos migran al sistema nervioso central y liberan citocinas como interleucinas 1 y 6 (IL-1, IL-6) y factor de necrosis tumoral (TNF), que actúan sobre células residentes del mismo. El sistema inmune innato desempeña un papel importante en el inicio y progresión de la enfermedad, mediante la identificación de patrones moleculares asociados con patógenos y daño, que modulan las funciones efectoras y reguladoras de las células donde se expresan, para dirigir la respuesta inmune específica. Las células Th17 favorecen la disrupción de la barrera hematoencefálica, que permite la migración de leucocitos al sistema nervioso central y desencadena la cascada de la inflamación; el perfil Th1 (IL-1, IL-6) colabora para perpetuarla. La función de las células B es la producción de anticuerpos y citocinas (IL-6, IL-12 y TFN). Conocer la fisiopatología de la esclerosis múltiple permitirá desarrollar nuevas opciones terapéuticas que impacten en la historia natural de la enfermedad y su pronóstico.


Assuntos
Citocinas/imunologia , Inflamação/fisiopatologia , Esclerose Múltipla/fisiopatologia , Animais , Barreira Hematoencefálica/metabolismo , Movimento Celular/fisiologia , Progressão da Doença , Humanos , Imunidade Inata/imunologia , Inflamação/imunologia , Leucócitos/metabolismo , Esclerose Múltipla/imunologia , Prognóstico , Células Th17/imunologia
6.
Expert Rev Clin Immunol ; 14(1): 83-93, 2018 01.
Artigo em Inglês | MEDLINE | ID: mdl-29202590

RESUMO

BACKGROUND: X-linked agammaglobulinemia (XLA) is characterized by the absence of immunoglobulin and B cells. Patients suffer from recurrent bacterial infections from early childhood, and require lifelong immunoglobulin replacement therapy. Mutations in BTK (Bruton's Tyrosine Kinase) are associated with this phenotype. Some patients that present XLA do not show typical clinical symptoms, resulting in delayed diagnosis due to the lack of a severe phenotype. This study presents a report of five XLA patients from four different families and attempts to determine a relationship between delayed diagnosis and the occurrence of BTK mutations. METHODS: Samples from patients with antibody deficiency were analyzed to determine BTK expression, immunophenotyping and mutation analysis. Clinical and laboratory data was analyzed and presented for each patient. RESULTS: Most patients presented here showed atypical clinical and laboratory data for XLA, including normal IgM, IgG, or IgA levels. Most patients expressed detectable BTK protein. Sequencing of BTK showed that these patients harbored missense mutations in the pleckstrin homology and Src-homology-2 domains. When it was compared to public databases, BTK sequencing exhibited a new change, along with three other previously reported changes. CONCLUSIONS: Delayed diagnosis and atypical manifestations in XLA might be related to mutation type and BTK expression.


Assuntos
Agamaglobulinemia/diagnóstico , Linfócitos B/imunologia , Doenças Genéticas Ligadas ao Cromossomo X/diagnóstico , Infecções/diagnóstico , Mutação de Sentido Incorreto/genética , Domínios de Homologia à Plecstrina/genética , Proteínas Tirosina Quinases/genética , Domínios de Homologia de src/genética , Adolescente , Adulto , Tirosina Quinase da Agamaglobulinemia , Criança , Pré-Escolar , Análise Mutacional de DNA , Diagnóstico Tardio , Humanos , Imunoglobulinas/sangue , Imunoglobulinas/deficiência , Imunofenotipagem , Fenótipo , Adulto Jovem
7.
Rev Med Inst Mex Seguro Soc ; 55(Suppl 4): S414-S418, 2017.
Artigo em Espanhol | MEDLINE | ID: mdl-29799713

RESUMO

Background: Bronchiectasis are permanent dilatations of the bronchi. Its prevalence in patients with variable common immunodeficiency (CVID) is high, however there is little information regarding the type and location of the same; therefore the objective of this study is to know the type and location of bronchiectasis in a cohort of adult patients with CVID. Methods: It has been made a transversal, observational and descriptive study that included 32 adult patients with diagnosis of CVID according to the criteria of the European Society of Immunodeficiencies (ESID). All patients underwent high resolution pulmonary computed tomography (HRCT), which were interpreted by an expert radiologist. The frequency, type and location of bronchiectasis were reported using descriptive statistics. Results: Thirty-two adult patients, ten men (31.25%) and 22 women (68.7%), were included. 40.6% had bronchiectasis. 23% had a lobe involvement, 15.3% two lobes, 46.1% 3 lobes and 15.3% complete involvement of the parenchyma. The types of bronchiectasis were distributed as follows: tubular 38.4%, varicose 23% and cystic and tubular combinations 15.3%, cystic and varicose 15.3% and cystic, tubular and varicose 7.6%. Conclusions: Our results show that 40% of adult patients with CVID have BQs, usually affecting three pulmonary lobes, located mainly in the right and middle lower lobe; The tubular type, is the most common. Their timely diagnosis and treatment can improve survival and reduce costs for patients and health care.


Introducción: Las bronquiectasias (BQs) son dilataciones permanentes de los bronquios. Su prevalencia en pacientes con inmunodeficiencia común variable (IDCV) es alta, sin embargo existe escasa información respecto al tipo y localización de las mismas. El objetivo de este estudio es conocer el tipo y localización de las bronquiectasias en una cohorte de pacientes adultos portadores de IDCV. Métodos: Estudio transversal, observacional y descriptivo que incluyó a 32 pacientes adultos con diagnóstico de IDCV de acuerdo con los criterios de la Sociedad Europea de Inmunodeficiencias. A todos se les realizó tomografía de alta resolución pulmonar, las cuales fueron interpretadas por un médico radiólogo experto. Se reportó la frecuencia, tipo y localización de las bronquiectasias mediante estadística descriptiva.Resultados: se incluyeron 32 pacientes adultos, diez hombres y 22 mujeres. El 40.6% presentaron bronquiectasias. El 23% tenía afección en un lóbulo, el 15.3% dos lóbulos, 46.1% 3 lóbulos y el 15.3% afectación completa del parénquima; distribuidos de la siguiente manera: tubulares 38.4%, varicosas 23% y las combinaciones quísticas y tubulares 15.3%, quísticas y varicosas 15.3% y quísticas, tubulares y varicosas 7.6%. Conclusión: Nuestros resultados muestran que el 40% de los pacientes adultos con IDCV tienen BQs, suelen afectar tres lóbulos pulmonares, el tipo más común fue el tubular. Su diagnóstico y tratamiento oportuno puede mejorar la supervivencia y reducir los costos para el paciente y las instituciones de salud.


Assuntos
Bronquiectasia/etiologia , Imunodeficiência de Variável Comum/complicações , Adulto , Bronquiectasia/diagnóstico por imagem , Bronquiectasia/epidemiologia , Bronquiectasia/patologia , Estudos Transversais , Feminino , Humanos , Masculino , Tomografia Computadorizada por Raios X
8.
Rev Esp Enferm Dig ; 108(11): 750-753, 2016 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-26875864

RESUMO

Intestinal intussusception rarely occurs in the adult population and accounts only for 1% to 5% of all the causes of intestinal obstruction. This complication is more frequent in the small bowel and can be due to different aetiologies, including inflammatory, infectious or neoplastic diseases. Malignancies account for 50% to 60% of all cases of colon invagination. The gastrointestinal (GI) tract is the most common site for extra-nodal non-Hodgkin lymphomas (NHL), representing 5% to 20% of all the cases. However, primary NHL of the GI tract is a very infrequent clinic-pathological entity and accounts only for 1% to 4% of all the neoplasms of the GI tract. Primary NHL of the colon is a rare disease and it comprises only 0.2% to 1.2% of all colonic malignancies. Here we describe a case of an AIDS adult patient who developed an intussusception secondary to a primary large B cell lymphoma of the transverse colon. English and Spanish literature was reviewed.


Assuntos
Doenças do Colo/etiologia , Neoplasias do Colo/complicações , Infecções por HIV/complicações , Intussuscepção/etiologia , Linfoma não Hodgkin/complicações , Adulto , Doenças do Colo/diagnóstico por imagem , Doenças do Colo/cirurgia , Humanos , Intussuscepção/diagnóstico por imagem , Intussuscepção/cirurgia , Laparotomia , Masculino
9.
Medicina (B Aires) ; 76(1): 10-8, 2016.
Artigo em Espanhol | MEDLINE | ID: mdl-26826987

RESUMO

Primary pyomyositis is a bacterial infection of striated muscle which is acquired by hematogenous route. It is related to risk factors such as HIV/aids and other immuno suppressing diseases, and can be associated with local muscle stress factors. The most frequent etiology is Staphylococcus aureus. Its diagnostic delay may cause a fatal evolution. In this series 32 patients with primary pyomyositis diagnosed by ultrasound were evaluated. The most frequent risk factor was HIV/aids (61%). Local factors were detected in 21 (66%) cases: first, the practice of football. The monofocal form was observed in 19 (59%), the most commonly affected muscles were quadriceps, calves and psoas. Samples for bacteriological study were obtained in 30 cases, 22 blood culture and 27 abscess materials. In 30 cases the etiologic agent was isolated. Staphylococcus aureus accounted for 83.3% (25 cases) and Escherichia coli, Nocardia spp., Streptococcus agalactiae, nontuberculous mycobacteria, Pseudomonas aeruginosa were isolated in one case each. Seventeen patients received surgical treatment, aspirative punctures, 9; antibiotics alone, 4. Twenty eight (93.3%) patients had a good evolution; deaths, 2 (6.6%); unknown, 2. Main conclusions of this study were: due to the diverse and changing etiology of the primary pyomyositis it is important to recognize the etiological agent involved and their antibiotic susceptibility. The ultrasound performed the study in real time so it can be used to guide the puncture and to facilitate the immediate diagnosis. This makes the difference with other techniques and transforms it into a first-line method for the study of this disease.


Assuntos
Piomiosite/diagnóstico por imagem , Infecções Estafilocócicas/diagnóstico por imagem , Staphylococcus aureus/isolamento & purificação , Adolescente , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Piomiosite/microbiologia , Piomiosite/terapia , Estudos Retrospectivos , Fatores de Risco , Infecções Estafilocócicas/microbiologia , Infecções Estafilocócicas/terapia , Tomografia Computadorizada por Raios X , Ultrassonografia , Adulto Jovem
10.
Medicina (B.Aires) ; Medicina (B.Aires);76(1): 10-18, feb. 2016. ilus, mapas, tab
Artigo em Espanhol | LILACS | ID: biblio-841532

RESUMO

La piomiositis primaria es la infección bacteriana por vía hematógena del músculo estriado. Está relacionada con factores de riesgo como HIV/sida y otras enfermedades inmunodepresoras, pudiendo estar asociados a factores locales de estrés muscular. El agente etiológico más frecuente es Staphylococcus aureus. Su retardo diagnóstico puede ocasionar una evolución fatal. En esta serie se evaluaron 32 pacientes con piomiositis primaria diagnosticados por ecografía. El factor de riesgo más frecuente fue el HIV/sida (61%). Los factores locales se detectaron en 21 casos (66%): en primer lugar, la práctica de futbol. La forma monofocal se observó en 19 (59%) los músculos más frecuentemente afectados fueron cuádriceps, gemelos y psoas. Se obtuvieron muestras para estudio bacteriológico en 30 casos, 27 de material del absceso y 22 hemocultivos. En los 30 casos se aisló el agente etiológico. El Staphylococcus aureus representó el 83.3% (25 casos) y Escherichia coli, Nocardia spp., Streptococcus agalactiae, Micobacteria no tuberculosa y Pseudomonas aeruginosa fueron aislados en un caso cada uno. Recibieron tratamiento quirúrgico 17 pacientes, punciones aspirativas, 9; antibióticos solamente, 4. Presentaron buena evolución 28 de los 30 pacientes (93.3%), óbitos, 2 (6.6%); desconocida, 2. Este estudio concluyó que: ante la etiología diversa y cambiante de las piomiositis primarias es importante reconocer el agente involucrado y su sensibilidad antibiótica. La ecografía realiza la evaluación en tiempo real y puede ser utilizada como guía de punción facilitando el diagnóstico inmediato. Esto la diferencia de otras técnicas, transformándola en un método de primera línea para el estudio de esta enfermedad.


Primary pyomyositis is a bacterial infection of striated muscle which is acquired by hematogenous route. It is related to risk factors such as HIV/aids and other immuno suppressing diseases, and can be associated with local muscle stress factors. The most frequent etiology is Staphylococcus aureus. Its diagnostic delay may cause a fatal evolution. In this series 32 patients with primary pyomyositis diagnosed by ultrasound were evaluated. The most frequent risk factor was HIV/aids (61%). Local factors were detected in 21 (66%) cases: first, the practice of football. The monofocal form was observed in 19 (59%), the most commonly affected muscles were quadriceps, calves and psoas. Samples for bacteriological study were obtained in 30 cases, 22 blood culture and 27 abscess materials. In 30 cases the etiologic agent was isolated. Staphylococcus aureus accounted for 83.3% (25 cases) and Escherichia coli, Nocardia spp., Streptococcus agalactiae, nontuberculous mycobacteria, Pseudomonas aeruginosa were isolated in one case each. Seventeen patients received surgical treatment, aspirative punctures, 9; antibiotics alone, 4. Twenty eight (93.3%) patients had a good evolution; deaths, 2 (6.6%); unknown, 2. Main conclusions of this study were: due to the diverse and changing etiology of the primary pyomyositis it is important to recognize the etiological agent involved and their antibiotic susceptibility.The ultrasound performed the study in real time so it can be used to guide the puncture and to facilitate the immediate diagnosis. This makes the difference with other techniques and transforms it into a first-line method for the study of this disease.


Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto , Adulto Jovem , Infecções Estafilocócicas/diagnóstico por imagem , Staphylococcus aureus/isolamento & purificação , Piomiosite/diagnóstico por imagem , Infecções Estafilocócicas/microbiologia , Infecções Estafilocócicas/terapia , Tomografia Computadorizada por Raios X , Estudos Retrospectivos , Fatores de Risco , Ultrassonografia , Piomiosite/microbiologia , Piomiosite/terapia
12.
Rev Alerg Mex ; 62(3): 251-4, 2015.
Artigo em Espanhol | MEDLINE | ID: mdl-26239335

RESUMO

Treatment of HIV infection requires the combination of multiple antiretroviral drugs, known as highly active antiretroviral therapy (HAART); however, up to 84% of patients experience adverse drug effects that lead to discontinuation within first months of treatment. Skin manifestations are reported to 22% of patients. The severity of these is variable, such as erythema multiforme, rash, hives and severe skin reactions at less than 2%. Mild rashes, usually transient and self-limiting, while severe reactions require immediately remove the drug involved to prevent progression of the reaction. Only in those cases where the offending drug does not have another alternative and documented the reaction is mediated type I hypersensitivity mechanisms, can be performed desensitization protocol.


El tratamiento para infección por VIH requiere la combinación de múltiples fármacos antirretrovirales, conocida como Terapia Antirretroviral Altamente Activa (TARAA), sin embargo hasta el 84% de los pacientes presentan efectos adversos a los fármacos, que los llevan a suspender el tratamiento dentro de los primeros meses de tratamiento. Las manifestaciones cutáneas se reportan hasta el 22.1% de los pacientes. La severidad de éstas es variable, como eritema multiforme, exantema, urticaria y reacciones cutáneas severas en menos del 2%. Los exantemas leves, suelen ser transitorios y autolimitados, mientras que las reacciones severas requieren retirar el fármaco implicado inmediatamente para prevenir la progresión de la reacción. Solamente en aquellos casos que el fármaco responsable no cuente con otra alternativa y se documente que la reacción este mediada por mecanismos de hipersensibilidad tipo I, se puede realizar protocolo de desensibilización.

14.
Rev Alerg Mex ; 62(2): 107-11, 2015.
Artigo em Espanhol | MEDLINE | ID: mdl-25958373

RESUMO

BACKGROUND: Common variable immunodeficiency is the primary immunodeficiency (CVID) frequently found in adults. Its prevalence is estimated from 1:25,000 to 75,000 alive newborns; there are variations by ethnic groups, it is estimated about 50-70% in Caucasian patients. Oral cavity lesions are rarely found in adult patients with CVID, there are reports about lesions on pediatric patients mostly caused by infections. OBJECTIVE: To describe the orofacial lesions (oral, maxillofacial and neck area) affecting adults with CVID. MATERIAL AND METHOD: A transversal, prospective study was done in patients with CVID attended at Specialties Hospital, CMN SXXI, Mexico City. Patients where examined by the oral and maxillofacial surgeon and clinical findings were reported, then the descriptive analysis of the lesions was done. RESULTS: We evaluated 26 patients, 16 female and 10 males, average age of 38.6 years. In 18/26 patients we found oral lesions on 7 different types. The most frequent was minor salivary glands hiperplasia (19/26),petechiae (12/26) and herpetic ulcers (7/26). In head and neck, we found 4 different lesions, the most common was lymphadenopathy <2cm (4/26). CONCLUSIONS: The immunologic alterations associated to CVID favors the development of lesions mainly of infectious and probably autoinmune origin that affects the oral cavity and head and neck area.


Antecedentes: la inmunodeficiencia común variable es la inmunodeficienci primaria más común en adultos. Su prevalencia se estima en 1 por cada 25,000 a 75,000 recién nacidos vivos; existen variaciones por grupos étnicos, se estima en 50 a 70% en pacientes de raza caucásica. Las lesiones de la cavidad oral raramente se describen en pacientes adultos con inmunodeficiencia común variable, en niños con esta enfermedad existen informes de lesiones principalmente de origen infeccioso. Objetivo: describir las lesiones orofaciales (cavidad oral, macizo facial y cuello) en pacientes adultos con inmunodeficiencia común variable. Material y método: estudio transversal, prospectivo, efectuado en todos los adultos con inmunodeficiencia común variable adscritos a la Clínica de inmunodeficiencias primarias, del Hospital de Especialidades, Centro Médico Nacional Siglo XXI, que fueron examinados por un cirujano maxilofacial; se realizó el reporte de hallazgos en lista de cotejo y, posteriormente, el análisis descriptivo de las lesiones. Resultados: se incluyeron 26 pacientes, 16 mujeres y 10 hombres, con edad promedio de 38.6 años. En 18 de 26 pacientes estudiados se observaron lesiones orales, con siete lesiones diferentes y predominio en el sexo femenino 2:1. Las lesiones más frecuentes fueron: hiperplasia de glándulas salivales menores (19/26), petequias (12/26) y úlceras herpetiformes (7/26). En la cara y el cuello se observaron cuatro lesiones distintas, las adenopatías < 2 cm (4/26) fueron las más comunes. Conclusiones: las alteraciones inmunológicas asociadas con la inmunodeficiencia común variable favorecen la aparición de lesiones de origen infeccioso y probablemente autoinmunitario que afectan la cavidad oral, la cara y el cuello.

15.
Rev Alerg Mex ; 62(2): 91-7, 2015.
Artigo em Espanhol | MEDLINE | ID: mdl-25958371

RESUMO

BACKGROUND: Common variable immunodeficiency (CVID) is the primary immunodeficiency with the largest number of comorbidities in adulthood. It has been associated with bronchiectasis between 17%-76%, and these with the presence of cardiovascular complications such as pulmonary hypertension and heart failure. The new image methods of diagnosis, to assess the cardiovascular structural and functional conformation of adult patients with bronchiectasis, help to establish more efficient and timely diagnoses. OBJECTIVE: To define the presence of structural and functional heart disease in CVID patients by transthoracic echocardiography. MATERIAL AND METHOD: A cross-sectional study was done in a cohort of 26 adult patients diagnosed with CVID and replacement therapy with intravenous immunoglobulin (IVIG), belonging to the Immunodeficiency Clinic. All patients underwent transthoracic echocardiography and tissue ECO doopler; the results were evaluated by a echocardiographer physician. RESULTS: We evaluated 26 patients, of whom 10 patients were male, with a mean age of 35.7 ± 13.7 years. The results of thoracic echocardiography of the left cardiac cavities found the following functional changes: 17 patients presented with mitral insufficiency and only 2 had aortic insufficiency, none symptoms. Regarding the structural alterations of the right cavities: 8 adults with CVID had right cavities growth and 5 of them, hypermobile atrial septum was reported; respect to functional alterations, 24 patients had tricuspid insufficiency; in 20 it was mild and only in 3 is was moderate. Up to 12 had pulmonary valve insufficiency, and 8 had pulmonary arterial hypertension (PAH); of which, in 2 it was mild and in one it was moderate; and 4 patients had PSAP in high limit values. CONCLUSIONS: Patients with CVID, despite having a high incidence of bronchiectasis, had low incidence of PAH, but a significant number of patients had PSAP in high cutoff level, so, these patients should be monitored annually, because probably they will evolve to PAH in the future. Also, they have a high incidence of mild valvular regurgitation due to mild degenerative changes with valvular sclerosis, therefore, they also require regular monitoring.


Antecedentes: la inmunodeficiencia común variable es la inmunodeficiencia primaria con mayor cantidad de comorbilidades en la vida adulta. Se ha asociado con bronquiectasias en 17 a 76%, y éstas, con complicaciones cardiovasculares, como hipertensión arterial pulmonar e insuficiencia cardiaca. Los nuevos métodos diagnósticos de imagen permiten evaluar la conformación estructural y funcional cardiovascular de los pacientes adultos con bronquiectasias y, de esta manera, establecer diagnósticos más eficientes y oportunos. Objetivo: determinar las cardiopatías estructurales y funcionales en pacientes con inmunodeficiencia común variable mediante ecocardiografía transtorácica. Material y método: estudio transversal, descriptivo, efectuado en una cohorte de 26 pacientes adultos con diagnóstico de inmunodeficiencia común variable y tratamiento sustitutivo con inmunoglobulina intravenosa (IgIV), pertenecientes a la Clínica de Inmunodeficiencias. A todos los pacientes se les realizó ecocardiografía transtorácica con ecocardiograma doppler y tisular; los resultados fueron evaluados por un médico cardiólogo ecocardiografista. Resultados: evaluamos a 26 pacientes; de ellos, 10 fueron del género masculino, con media de edad de 35.7 ± 13.7 años. Los resultados de la ecocargiografia torácica en las cavidades cardiacas izquierdas reportaron las siguientes alteraciones funcionales: 17 de 26 pacientes tuvieron insuficiencia mitral y sólo 2 tuvieron insuficiencia aórtica; ninguno de ellos con síntomas. Respecto de las alteraciones estructurales de las cavidades derechas: 8 pacientes adultos con inmunodeficiencia común variable tuvieron crecimiento de las cavidades derechas y en 5 pacientes se encontró tabique interauricular delgado e hipermóvil; respecto de las alteraciones funcionales, 24 pacientes tuvieron insuficiencia tricuspídea, en 21 de ellos fue leve y sólo en 3 fue moderada. Además, 12 pacientes tuvieron insuficiencia de la válvula pulmonar y 6 pacientes tuvieron hipertensión arterial pulmonar; de ellos, en 2 sujetos fue leve y en 2, moderada y 4 pacientes tuvieron presión sistólica de la arteria pulmonar con valores límites altos. Conclusiones: los pacientes con inmunodeficiencia común variable, a pesar de tener alta incidencia de bronquiectasias, tienen baja incidencia de hipertensión arterial pulmonar; pero un número importante de pacientes tiene presión sistólica de la arteria pulmonar con valor límite alto, por lo que estos pacientes deben tener un seguimiento anual, debido a que probablemente evolucionarán a hipertensión arterial pulmonar. Además, tienen alta incidencia de insuficiencias valvulares leves debido a cambios degenerativos con esclerosis valvular, por lo que también requieren vigilancia periódica.

16.
Rev Alerg Mex ; 62(1): 22-7, 2015.
Artigo em Espanhol | MEDLINE | ID: mdl-25758110

RESUMO

BACKGROUND: Common variable immunodeficiency (CVID) implies an increased risk of cancer, with an estimated incidence of 11-13%, particularly during the 5th and 6th decade of life. B cell-Hodgkin lymphomas are the more frequent cancer, followed by non-Hodgkin lymphoma and epithelial tumors (gastric, breast, bladder and cervix). OBJECTIVE: To describe the types of cancers in a cohort of adult patients with CVID. MATERIAL AND METHOD: An observational, cross-sectional and descriptive study was made in which we reviewed the charts of patients with CVID attending the Primary Immunodeficiencies Clinic at Specialties Hospital Dr. Bernardo Sepulveda, Centro Medico Nacional Siglo XXI, Mexico City. RESULTS: There were included 23 patients with CVID diagnosis, 13 women (56%) and 10 men (44%), with an average age of 36.7 years. Four patients developed malignancies (2 men and 2 women), with a prevalence of 17.3%. The types of cancers in this group of patients were: B cell-Hodgkin lymphoma (1/23), neuroendocrine carcinoma of the pancreas (1/23), myeloid chronic leukemia (1/23) and thyroid papillary carcinoma (1/23). In two of the subjects the diagnosis of cancer was established previous to CVID diagnosis. The average age of diagnosis of cancer was 27 years (19-34 years). CONCLUSIONS: In our patients we found different types of malignancies compared to previously described. We consider necessary a screening protocol for an early diagnosis of cancer in these patients. The frequency of cancer in our population was the same as reported in the literature.


Antecedentes: los pacientes con inmunodeficiencia común variable tienen riesgo elevado de padecer enfermedades neoplásicas, con incidencia de 11 a 13%, especialmente durante la quinta y sexta décadas de la vida. Los linfomas de tipo celular B son los más frecuentes, además del linfoma no Hodgkin y tumores epiteliales (carcinomas de estómago, mama, vejiga y cuello uterino). Objetivo: conocer el tipo de enfermedades neoplásicas en una cohorte de pacientes adultos con inmunodeficiencia común variable. Material y método: estudio observacional, transversal y descriptivo, en el que se revisaron los expedientes con diagnóstico de inmunodeficiencia común variable de la Clínica de Inmunodeficiencias Primarias del servicio de Alergia e Inmunología Clínica del Hospital de Especialidades del Centro Médico Nacional Siglo XXI del IMSS. Resultados: se incluyeron 23 pacientes con diagnóstico de inmunodeficiencia común variable; de éstos, 13 (56%) eran mujeres, el promedio de edad fue de 36.7 años. Se encontraron neoplasias en cuatro pacientes de este grupo (dos mujeres y dos hombres), la prevalencia de cáncer fue de 17.3%. Los tipos de cáncer reportados fueron: linfoma Hodgkin de células B (1/23), carcinoma neuroendocrino de la cabeza del páncreas (1/23), leucemia mieloide crónica (1/23) y cáncer papilar de tiroides (1/23). En dos de los pacientes, el diagnóstico de cáncer fue previo al diagnóstico de la inmunodeficiencia primaria. El promedio de edad al momento del diagnóstico de cáncer fue de 27 años (límites: 19-34 años). Conclusión: la frecuencia de cáncer en nuestra población fue similar a lo reportado en la bibliografía. Sin embargo, los tipos de cáncer fueron distintos a lo publicado. Consideramos que es necesario realizar un protocolo de escrutinio en estos pacientes para diagnosticar de manera oportuna cualquier tipo de neoplasia, debido al mayor riesgo que tienen estos pacientes.

17.
Rev Alerg Mex ; 61(3): 131-40, 2014.
Artigo em Espanhol | MEDLINE | ID: mdl-25177848

RESUMO

BACKGROUND: Common variable immunodeficiency (CVID) is the most frequent symptomatic primary immunodeficiency, affecting 1:25,000-75,000 people. It is characterized by the absence or decrease antibody production. Treatment for CVID consists on human immunoglobulin administration, and the intravenous route is the most common route for administration, at 400-800 mg/kg of weight every 3-4 weeks. Adverse effects associated with intravenous immunoglobulin (IVIg) use occur in 25% of all infusions, with severe adverse reactions presenting in less than 1% of all patients. Acute renal failure can occur as a severe adverse reaction, which presents 1-10 days after starting IVIg treatment. In our center we implemented an ambulatory scheme for IVIg administration, which allows its administration in an average of 3 hours, without severe adverse effects. OBJECTIVES: To describe adverse effects and to evaluate the frequency of renal failure secondary to ambulatory IVIg administration in patients with common variable immunodeficiency. MATERIAL AND METHOD: A descriptive and prospective study was done including adult patients con definitive diagnosis of common variable immunodeficiency, receiving IVIg at replacement dose every 3 weeks. All patients were evaluated with clinical exploration, somatometry, serum creatinine, albumin and urea determination, 24 hours creatinine clearance, glomerular filtration rate with CKD-EPI, and immediate renal function associated with accumulated IVIg. Results were analyzed with descriptive statistics. RESULTS: We determined adverse effects in 25 patients with common variable immunodeficiency (15 women and 10 men, average age 36.7 years), during a 10 months period (January-September 2013). During this period 284 IVIg infusions were administered using our scheme, frequency of adverse effects were 12.9%, with 5.2% of early adverse effects and 7.7% late adverse effects, all being mild to moderate, in some cases required analgesic and/or antihistamine administration, without having to stop the IVIg infusion. In the renal function study 19 patients were included (12 women and 7 men, average age 36 years, average weigh 58.74 kg and average height 1.60 m), evaluated from January 2009 to October 2013. Average serum creatinine was 0.76 ± 0.18 mg/dL, average serum urea was 28.6 ± 7.6 mg/dL, none patient presenting acute renal failure. Glomerular filtration rate was determined with CKD-EPI formula, and the average was 116 ± 34 mL/min/1.73 m2, finding chronic renal failure in 4 patients. Average 24 hours creatinine clearance was 98.64 ± 22 mL/min/1.73 m2, with chronic renal failure data in 6 patients. CONCLUSIONS: There were no severe adverse effects with this ambulatory IVIg scheme (anaphylaxis, acute renal failure). We did not find data of acute renal failure secondary to IVIg administration in this population, but we did find data of chronic renal failure secondary to IVIg administration through 24 hours creatinine clearance in 6 patients. No relation was found between accumulated IVIg dose in the last 5 years and decreased glomerular filtration rate. Another benefit worth of mentioning with this scheme is the reduction in costs for the health institution and to the patient.


Antecedentes: la inmunodeficiencia común variable es la inmunodeficiencia primaria sintomática más frecuente, afecta a 1 por cada 25,000 a 75,000 sujetos. Se distingue por la ausencia o disminución de anticuerpos. Su tratamiento consiste en el reemplazo de anticuerpos con inmunoglobulina humana y la vía de administración más frecuente es la intravenosa, a dosis de 400 a 800 mg/kg de peso/dosis cada tres a cuatro semanas. Los efectos adversos asociados con la administración de inmunoglobulina intravenosa (IgIV) ocurren incluso en 25% de todas las infusiones realizadas, las reacciones severas afectan a menos de 1% de los pacientes. Entre las reacciones adversas severas están la insuficiencia renal aguda, que sobreviene 1 a 10 días después del inicio de tratamiento con IgIV. En nuestro centro elaboramos e implementamos un esquema ambulatorio para la aplicación de IgIV que permite su administración en un promedio de 3 h, sin efectos adversos graves. Objetivos: describir los efectos adversos y evaluar la frecuencia de insuficiencia renal secundaria a la aplicación ambulatoria de IgIV en pacientes adultos con inmunodeficiencia común variable. Material y método: estudio descriptivo y prospectivo en el que participaron pacientes adultos con diagnóstico definitivo de inmunodeficiencia común variable, que recibían IgIV a dosis de sustitución cada tres semanas, a quienes se realizó exploración física, somatometría, determinación sérica de creatinina, albúmina y urea, depuración de creatinina en orina de 24 horas, cálculo de la tasa de filtración glomerular por la fórmula CKD-EPI y evaluación de la función renal inmediata, así como la asociada con la administración acumulada de IgIV a través del cálculo de la tasa de filtración glomerular. Los resultados se analizaron con estadística descriptiva para el reporte de los efectos en la función renal y la dosis acumulada de IgIV. Resultados: se determinó la frecuencia de reacciones adversas en 25 pacientes con diagnóstico de inmunodeficiencia común variable (15 mujeres y 10 varones, con edad promedio de 36.7 años), durante un periodo de 10 meses (enero a septiembre de 2013). En este periodo se aplicaron 284 infusiones de IgIV utilizando el esquema propuesto, la frecuencia de reacciones adversas fue de 12.9% del total de las infusiones, de las que 5.2% fueron reacciones adversas tempranas y 7.7% reacciones adversas tardías, todas fueron reacciones leves a moderadas, que ameritaron en algunos casos la administración de analgésico, antihistamínico o ambos, sin llegar a requerirse la suspensión de la infusión de IgIV. En el estudio de la función renal se incluyeron 19 pacientes (12 mujeres y 7 hombres, edad promedio 36 años, peso promedio 58.74 kg y talla promedio 1.60 m) y en el lapso estudiado (enero de 2009 a octubre de 2013) la determinación de creatinina en promedio fue de 0.76 ± 0.18 mg/dL; la urea sérica promedio del grupo fue de 28.6 ± 7.6 mg/dL, ningún paciente tuvo datos de insuficiencia renal aguda. La tasa de filtración glomerular se determinó mediante la fórmula de CKD-EPI y fue, en promedio, de 116 ± 34 mL/min/1.73 m2, se encontraron datos de deterioro renal crónico en cuatro pacientes. La determinación promedio de la depuración de creatinina en orina de 24 horas fue de 98.64 ± 22 mL/min/1.73 m2 y se encontraron datos de deterioro crónico en la función renal en seis pacientes. Conclusiones: con este esquema ambulatorio de aplicación de IgIV no hubo reacciones adversas graves (anafilaxia, broncoespasmo, insuficiencia renal aguda). En esta población de pacientes no se encontró afección renal aguda secundaria a la aplicación de IgIV, pero mediante la depuración de creatinina de 24 horas sí se encontraron datos que sugirieron daño renal crónico en seis pacientes. No se encontró relación entre la dosis acumulada de IgIV aplicada en los últimos cinco años con el hallazgo de disminución de la tasa de filtración glomerular. Otro beneficio de este método de aplicación de IgIV es la reducción en los costos para la institución de salud y para el paciente, además de permitir a éste reintegrarse a sus actividades cotidianas laborales o escolares de manera rápida.

18.
Rev Alerg Mex ; 61(3): 147-52, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-25177850

RESUMO

BACKGROUND: The prevalence of pollinosis has doubled in the past two decades. Several studies suggest that up to 50% of adult residents of Mexico City can present manifestations of respiratory allergy, and pollens from trees, grasses and weeds are a common cause. To determine the prevalence of their families and antigenic cross-reactivity allows us to offer appropriate diagnoses and treatments. OBJECTIVE: To know the prevalence of sensitization of pollens to trees, grasses and weeds in adults with respiratory allergy of the South zone of Mexico City from January 2007 to December 2013. MATERIAL AND METHOD: A cross-sectional, observational and prospective study was done with patients from Mexico City, referred to the National Medical Center Siglo XXI, IMSS, from 2007 to 2013 with a diagnosis of allergic rhinitis, asthma and conjunctivitis. We analyzed the results of skin prick tests to pollens from trees, grasses and weeds in selected patients. The results were analyzed using descriptive statistics. RESULTS: A total of 672 patients were analyzed, 70% men, the average age was 34 ± 16 years. Regarding occupation 31% were students, 48% employees and 21% housewives. Fifty-three percent had rhinitis, 47% had asthma and 40.5% had both, asthma and rhinitis. Prevalence of sensitization to weeds was 56%, 33% to trees and 11% to grasses. CONCLUSIONS: Sensitization to weeds is the first cause of respiratory pollinosis in the south of Mexico City, Amaranthus was the most prevalent pollen in this area. Sensitization to trees is the second cause, with a predominance of trees form Betulaceae, Fagaceae and Oleacea families. Sensitization to grass is the third cause of respiratory pollinosis. The most common are from Pooideae (Lolium perenne), Chloroideae and Cynodon/Dactylon family.


Antecedentes: la prevalencia de la polinosis se ha duplicado en las últimas dos décadas. Diversos estudios sugieren que incluso 50% de los adultos residentes del Distrito Federal pueden tener datos de alergia respiratoria y que los pólenes de árboles, pastos y malezas constituyen una causa frecuente. Conocer la prevalencia de sus familias y cruces antigénicos permite ofrecer diagnósticos y tratamientos adecuados. Objetivo: conocer la prevalencia de sensibilización a pólenes de árboles, gramíneas y malezas en adultos con alergia respiratoria de la zona sur del Distrito Federal en el periodo de enero de 2007 a diciembre de 2013. Material y método: estudio transversal, observacional y retrospectivo efectuado con pacientes que acudieron al servicio de Alergia e Inmunología Clínica del Hospital de Especialidades Dr. Bernardo Sepúlveda del Centro Médico Nacional Siglo XXI de la Ciudad de México, de 2007 a 2013, con diagnóstico de rinitis, asma y conjuntivitis alérgica. Analizamos los resultados de las pruebas cutáneas para pólenes de árboles, gramíneas y malezas de los pacientes. Los resultados se analizaron mediante estadística descriptiva. Resultados: se incluyeron 672 pacientes, 70% hombres, la edad promedio fue de 34 ± 16 años. En relación con su ocupación 31% eran estudiantes, 48% trabajadores y 21% amas de casa. El 53% tenía rinitis alérgica, 47% asma y 40.5% tenía ambos padecimientos. Se encontró prevalencia de sensibilización a malezas de 56%, a árboles de 33% y a gramíneas de 11%. Conclusiones: la sensibilización a malezas constituye en México la primera causa de polinosis respiratoria de la zona sur del Distrito Federal, el polen del amaranto fue el más prevalente en esta zona. La sensibilización a los árboles es la segunda causa de polinosis, con predominio de las familias Betulaceae, Fagaceae y Oleacea. La sensibilización a gramíneas constituye la tercera causa de polinosis respiratoria. Las más frecuentes son la familia Pooideae (Lolium perenne) y la familia Chloroideae (Cynodon dactylon).

19.
Rev Alerg Mex ; 61(3): 219-23, 2014.
Artigo em Espanhol | MEDLINE | ID: mdl-25177856

RESUMO

Wiskott-Aldrich syndrome was first reported clinically in 1937, and in 1954 the classic triad was identified: eccema, recurrent infections and thrombocytopenia with an X-linked transmission. Its incidence is estimated at 1 to 10 in one million live births per year. Wiskott Aldrich syndrome is caused by mutations in a gene in the short arm of chromosome X that encodes the Wiskott-Aldrich syndrome protein (WASp), which identification and sequencing was first performed in 1994, and since then about 300 mutations have been reported. This paper describes the case of a boy with Wiskott-Aldrich syndrome, with clinical and genetic diagnosis, with a considerable diagnostic delay attributable to an atypical presentation misdiagnosed as immune thrombocytopenia.


El síndrome de Wiskott Aldrich fue descrito en 1937 y en 1954 se identificó su tríada característica: eccema, infecciones recurrentes y trombocitopenia, con herencia ligada al cromosoma X. Su incidencia se calcula en 1 a 10 por cada millón de recién nacidos vivos por año. Su causa es la mutación del gen localizado en el brazo corto del cromosoma X, que codifica la proteína del síndrome Wiskott-Aldrich (WASp), cuya identificación y secuenciación se realizan desde 1994, lo que ha permitido describir al menos 300 defectos genéticos. Comunicamos un caso de síndrome de Wiskott-Aldrich con diagnóstico clínico y genético, tipo nonsense Q203X, en el exón 7, en un preescolar con ausencia de eccema.

20.
Rev Alerg Mex ; 61 Suppl 1: S1, 2014.
Artigo em Espanhol | MEDLINE | ID: mdl-24941971
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA